about
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.A peripheral circulating compartment of natural naive CD4 TregsAntibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factorsAntigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.Consensus nomenclature for CD8(+) T cell phenotypes in cancerVaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.Modulation of Cytokine Secretion Allows CD4 T Cells Secreting IL-10 and IL-17 to Simultaneously Participate in Maintaining Tolerance and ImmunityCD4(+) T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs.Tinkering with nature: the tale of optimizing peptide based cancer vaccines.MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer.Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t.An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-exAssessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells.Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functions.Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo.Ex vivo IL-1 receptor type I expression in human CD4+ T cells identifies an early intermediate in the differentiation of Th17 from FOXP3+ naive regulatory T cells.Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content.A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival.Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer.CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitroEpitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigenA monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3+ LGL-leukemiaAnalysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass spectrometry: application to the design of peptidase-resistant analogsA new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapyRapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ TLentivector immunization induces tumor antigen-specific B and T cell responses in vivoDistinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1
P50
Q33841896-808EC759-78EA-427C-93D9-26506BC309AFQ33865874-1D84E67C-6D66-485A-9BEE-FC470A1542C2Q33957896-269EA36D-3B20-43F4-B0FE-BFE98CF01672Q33987977-6B8CD61D-7088-48A7-AA12-83D833F17158Q34320455-10EA955D-03B7-4748-98BB-738DAA888D24Q35005935-05D3FF1C-54EA-4D0A-A76F-6F63CFD78753Q35039508-F9B5ACE1-024E-4A06-87DF-3C9288BFFA82Q35798822-E62A0DC8-3FBA-4910-AA63-CB41AD8C38E2Q35829136-70834CBB-D8B9-43DF-B4B0-0BC5ABCC0EA1Q35879447-1B2EA898-CFA5-4006-B6C0-A4C0F8C3792BQ36256035-06349C26-43CF-4C3E-937F-3C760CC01025Q36280096-311A476A-BA38-44A9-B133-7013C3AF1B14Q36579158-EF1AA5D6-3B2C-4332-8EAA-EC2D0421774CQ36821194-3216AB52-CC74-4537-8416-A01C33168B21Q37208910-A1DABB27-E7F8-4554-B585-47F9EB20BD25Q37370515-FC3AE40A-95B1-447B-8A0C-DACC873D8964Q39314045-E17F0D9D-F1F8-4093-ABAD-C878BCBB7DF0Q39880448-67BDCDB0-C02B-408F-9FC2-F347C954FD24Q40191033-607AD081-45D7-4E1D-A300-7352E4E4FE3EQ40782201-EA273ECE-651E-4898-8BE7-1554FF0C6CDAQ40963061-A22DAF02-E8BF-4EBB-8742-B0A03B802189Q43409719-17F2582E-4F26-4C4D-A903-B236E691C48CQ47578463-F2F0D6CC-2328-460C-92F1-5C156AFEBA80Q50972606-79F5AD77-68A0-410F-BA87-6A14DF05C506Q50987797-11D0D150-A994-43BD-9F07-62268DE6EF3DQ51803517-7BDB8CC8-1E38-46EF-8894-1A7B310F7C78Q51979456-2B46903E-44F0-4A4B-A42D-1A0B4028E359Q53643421-17DF71AC-14CA-4A6A-8179-0A5F7B375549Q53668096-2F6B8D11-0F2B-440B-872E-1F401D95A02EQ54378690-BD1B153D-1E7C-4B4F-8628-B7DC410873D7Q54528048-1EC4FFFC-9E2B-4E8E-AEEA-AE4F93AB2B2AQ54582568-D098B139-E750-4C39-AE70-95F2EFB81C2EQ59822912-D5BF537F-4AAA-40C8-BED6-83F7806D5921Q63436914-F7145B47-97FB-40D6-8424-DC236D81042FQ73413271-7C59FB93-1CAB-4C2C-A7C2-A13D8259B1AAQ74550246-82B39F6E-F366-423C-8D05-E66F1B37D0EAQ77137002-1ABA8FFB-BCA2-4210-BFFD-8671502160ADQ79834605-C3F1988B-A53F-49D5-A98A-81B5D2B0A6CDQ81436639-F86E559C-283D-4323-8D1F-A066FD23745BQ81663241-CCFEFE7E-A3F3-4580-8601-6C87FCED21AF
P50
description
researcher
@en
wetenschapper
@nl
name
Maha Ayyoub
@en
Maha Ayyoub
@nl
type
label
Maha Ayyoub
@en
Maha Ayyoub
@nl
prefLabel
Maha Ayyoub
@en
Maha Ayyoub
@nl
P106
P31
P496
0000-0003-2022-0898